share_log

美亚光电(002690)23年年报点评:传统主营业务高增 看好医疗设备板块布局

Meiya Optoelectronics (002690) Annual Report Review: Strong growth in traditional main business, optimistic about the layout of the medical equipment sector

東北證券 ·  Apr 9

Incidents:

The company released its annual results report for the year 23, achieving annual revenue of 2,425 billion yuan (+14.6%), achieving net profit attributable to shareholders of listed companies of 745 million yuan (+2.0%), and net profit attributable to shareholders of listed companies of 695 million yuan (-1.1%) after deducting non-recurring profit and loss.

Comment:

Profit performance declined slightly, and overall profitability remained steady. 1) Achieved a gross profit margin of 51.5% (-1.5pct) in 2023, achieving a net profit margin of 30.7% (-3.8pct), and achieved a net profit margin of 28.6% (-4.5pct) after deduction. The decline in profit margin was mainly due to the impact of the dental CBCT terminal price war and a slight increase in the cost structure, and overall profitability remained steady; 2) The company's period rate of 20.0% (+3.0pct), of which the sales/management/ R&D/ finance ratio was 11.7%/4.3%/6.1% /- 2.1%, +0.9/-0.8/+0.3/+2.5pct year over year. Increased sales investment is conducive to continuing to increase domestic market share while speeding up overseas market layout; increasing R&D expenses help product iteration and new product development, which is expected to consolidate the company's competitiveness in the long term.

Product side: New products continue to be introduced, and the product matrix in the medical equipment section continues to improve. 1) The color sorter section released a variety of new products, such as the industry-first UV color sorter, UHD deep learning color sorter, integrated plastic bottle sorting equipment, etc.; 2) The X-ray inspection section released a new X-ray inspection machine for small and medium-sized packaging and bottled food to comprehensively improve the scope of identification and inspection efficiency; 3) The medical equipment sector continues to iterate and upgrade and develop new products. ① Released a new high-end seated dental CBCT, with obvious advantages in terms of visibility, clarity, comfort, intelligence, and stability; ② Officially released the “American and American Dental” digital cloud platform for oral health to help achieve intelligent diagnosis and treatment; ③ 23Q1, spinal surgery navigation equipment obtained a medical device registration certificate, and the company made breakthrough progress in the field of non-dental high-end medical imaging; ④ 24Q1, mobile head CT obtained medical device registration certificates. The long-term performance potential of the medical sector is worth looking forward to.

The traditional machinery sector has maintained a relatively high growth rate, and the medical equipment sector is expected to contribute the second growth curve. 1) The color sorter segment has revenue of 1,476 billion yuan (+19.4%), and the X-ray inspection machine segment's revenue is 157 million (+61.0%). The company has established strong product advantages and brand barriers in traditional business fields, and the growth rate is expected to be maintained; 2) Continuously enriching the medical equipment product matrix and launching new products in the field of high-end imaging equipment and surgical navigation equipment. As commercialization of related products progresses, it is expected to contribute a second growth curve to the company.

Profit forecast and investment advice: The company is one of the leading companies in the dental CBCT field, and the product pipeline continues to improve. We expect the company to achieve revenue of 27.99/31.92/3.66 billion yuan and net profit to mother of 841/9.38/1,058 million yuan in 2024-2026, corresponding PE 19/17/15 times, respectively. Based on its advantages in the field of dental imaging equipment, the company expanded its business boundaries to the field of non-dental CT/surgical robots. The medical equipment sector layout was initially effective. It was optimistic about the company's long-term development expectations, covered for the first time, and gave it an “increase” rating.

Risk warning: Overseas expansion falls short of expectations, and market competition increases risk.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment